PRESS RELEASE. Sciety’s portfolio company PeptiSystems has secured an investment from Rubicon Healthcare Partners, making Rubicon a new shareholder in the company. The investment strengthens PeptiSystems’ position in a rapidly growing market segment and marks the next step in its international expansion. PeptiSystems develops and sells synthesis instruments that streamline
PRESS RELEASE. Sciety has led a SEK 40 million financing round for Hälsa Hemma, a Swedish healthtech company building next-generation primary care through its proprietary, integrated care platform. Through its digiphysical model, combining digital accessibility and efficiency with personal, in-home care, Hälsa Hemma is transforming how and where primary care
INSIGHT. A new generation of predictive health is emerging at the intersection of artificial intelligence and life science. Researchers at the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ) and the University of Copenhagen have developed Delphi-2M, a generative AI model that predicts the risk of developing
INSIGHT. Crossing the blood-brain barrier has long been one of the greatest challenges in drug development. Now we’re seeing technological breakthroughs that open the door for new treatments of neurodegenerative diseases, an area with great medical need and growing investment interest. A smart protection, but also a barrier to treatment
PRESS RELEASE. Sciety has strengthened the board of its portfolio company PeptiSystems by appointing Nick Roelofs – a strategic addition that significantly enhances the company’s ability to scale global sales and build strong industrial partnerships within advanced pharmaceutical manufacturing. The appointment is part of Sciety’s broader strategy to actively contribute specialist
PRESS RELEASE. Sciety’s portfolio company Pharmability (fd TIRmed) has strengthened its board with the appointment of Peder Walberg – a strategic addition as the company advances the development of a promising new treatment for atopic dermatitis (eczema). The appointment is the result of a targeted recruitment process carried out in close